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LiverAcetylcholinesterase (AChE), the enzyme that rapidly splits acetylcholine into acetate and choline, presents non-
cholinergic functions through whichmay participate in the control of cell proliferation and apoptosis. These two
features are relevant in cancer, particularly in hepatocellular carcinoma (HCC), a very aggressive liver tumorwith
high incidence and poor prognosis in advanced stages. Herewe explored the relation between acetylcholinester-
ase and HCC growth by testing the inﬂuence of AChE on proliferation of Huh-7 andHepG2 cell lines, addressed in
monolayer cultures, spheroid formation and human liver tumor samples. Results showed a clear relation in AChE
expression and cell cycle progression, an effectwhich depended on cell conﬂuence. Inhibition of AChE activity led
to an increase in cell proliferation, which was associated with downregulation of p27 and cyclins. The fact that
Huh-7 and HepG2 cell lines provided similar results lent weight to the relationship of AChE expression with
cell cycle progression in hepatoma cell lines at least. Human liver tumor samples exhibited a decrease in AChE
activity as comparedwith normal tissue. The evidence presented herein provides additional support for the pro-
posed tumor suppressor role of AChE, which makes it a potential therapeutic target in therapies against hepato-
cellular carcinoma.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Liver diseases represent one of the main challenges in public health
particularly in Mexico and South American countries. Changes in
human habits tend to increase the prevalence of grave liver diseases,
such as cirrhosis, viral hepatitis and liver cancer [1]. Hepatocellular car-
cinoma (HCC) is one of the most prevalent and aggressive tumors
worldwide with high rate of postsurgical recurrence [2,3], and, despite
the outstanding progress made in the last decade in identifying new
therapeutic approaches to target canonical proliferation and survival
pathways, the potential use of non-canonical molecules and the molec-
ular basis of their anti-proliferating activity are currently being studied
as a means to provide new therapeutic targets [4].Salud, Universidad Autónoma
l. Vicentina, 09340 Iztapalapa,
livares), legq@xanum.uam.mxIn spite of the well-known action of acetylcholine (ACh) at
cholinergic synapses, in the last few years ACh has been positioned as
a key regulator of survival, differentiation andproliferation [5]. Accumu-
lated evidence indicates that ACh and the range of proteins making the
so-called cholinergic operator have gained relevance in tumorigenesis
[6,7]. The cholinergic operator, which consists of high-afﬁnity
choline transporters (ChT), the ACh-synthesizing enzyme choline ace-
tyltransferase (ChAT), the message transducer nicotinic (nAChR) and
muscarinic (mAChR) receptors, and the ACh-hydrolyzing enzyme cho-
linesterases (ChEs), provides a molecular device for controlling spatial
and temporal effects of ACh. Most cell types express two classes of
ChEs: AChE (EC number 3.1.1.7) and BuChE (EC number 3.1.1.8). Al-
though AChE is the principal hydrolytic enzyme in excitable tissues
such as the brain, nerve and skeletal muscle, BuChE can functionally re-
place itwhenAChE is greatly reduced or suppressed [8]. Visceral organs,
such as the placenta, intestine, kidney, heart, liver, pancreas and thymus
contain variable amounts of both AChE and BuChE activities [9].
Besides their hydrolyzing action, both AChE and BuChE seem to play
non-catalytic roles, which would explain their wide distribution in tis-
sues and cells, including stem cells [10]. Experimental evidence links
Fig. 1. Effect of cell density on theAChEprotein level. A–H)Huh-7 cellswere plated at the cell densities indicated inMaterials andmethods. Representative images of at least 6 independent
experiments are shown. Originalmagniﬁcation at 50 and 320×. I)Whole cell lysate was obtained and subjected toWestern blotting. Representative immunoblot images. J) Densitometric
analysis of the protein content relative to actin used as loading control. Each column represents mean ± SEM of three separate experiments. Differences were considered signiﬁcant at
***p ≤ 0.0001 vs 47 × 103 cells/cm2 cell density.
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tein partners. Thus, it has been reported that AChE can interact with
laminins and collagen IV, amyloid β-peptide and presenilin-1, neuronal
enolase, the scaffold protein RACK1 and PKC, the co-repressor CtBP, the
Ran-binding protein, and a peptide fragment of AChE with nAChR [11].Fig. 2. Inﬂuence of the cell density on the levels of AChE protein and activity. A)Whole cell lysat
or absence of fetal bovine serum (FBS). RepresentativeWestern blot images are shown. B)Densi
cells cultured without and with FBS at LD and HD. AChEwas assayed as described inMaterial a
levels in HepG2 cells cultured without FBS and at LD and HD. Each column represents mean ±
**p ≤ 0.001 or ***p≤ 0.0001 vs LD.In addition, BuChE can also exert non-catalytic actions, as judged
by the role of the BuChE-K-apolipoprotein Eε4-amyloid β-peptide com-
plex in Alzheimer, and of BuChE itself inmegakaryocytopoiesis suppres-
sion and retinal cell differentiation [11,12]. Through non-catalytic
actions, AChE seems to participate directly or indirectly in motility,es were obtained from cell cultured at low (LD) and high density (HD), and in the presence
tometry data depicting the AChE protein content relative to actin. C) AChE activity levels in
nd methods. D) Image and densitometry analysis of AChE protein bands and AChE activity
SEM of three separate experiments. Differences were considered signiﬁcant at *p ≤ 0.05,
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reports dealing with the altered expression of AChE in a wide range of
tumor classes [13], along with the well-documented capacity of AChE
to halt the cell cycle progression [14] and to promote apoptosis by facil-
itating the apoptosome assembly [15–17] raise the possibility that AChE
collaborate to carcinogenesis through different pathways. The reports
showing that AChE functions as a tumor growth suppressor in hepato-
cellular carcinoma [18,19] and in non-small cell lung cancer, in the latter
via suppression by an AChE-targeted microRNA-212 [20] lend strong
support to the relationship of AChE with tumorigenesis.
The present work was addressed to gain a further insight into the
contribution of AChE to malignancy. With this aim, the hepatocellular
carcinoma (HCC) Huh-7 and HepG2 cell lines along with human HCC
samples were used for testing AChE inﬂuence on the cell proliferation
and spheroid formation.
2. Materials and methods
2.1. Cell culture
The Huh-7 andHepG2 cell lines, both derived from a humanhepato-
cellular carcinoma (HCC), were obtained from the American TypeFig. 3. Cell cycle related protein content. Whole cell lysates were obtained from low cells cultur
analysis of theWestern blots of Huh-7 cells, B) Representative images of theWestern blots of He
independent experiments. Differences were considered signiﬁcant at *p≤ 0.05 vs LD or **p ≤Culture Collection (ATCC, Rockville, MD, USA). Cells were cultured in
Williams-fetal bovine serum (Williams-FBS) medium consisting of
Williams medium supplemented with 10% fetal bovine serum (FBS,
Hy-Clone, Logan, UT, USA), 100 U/ml ampicillin and 100 μg/ml strepto-
mycin (Microlab,Mexico). Cellsweremaintained at 5% CO2, 90% humid-
ity, and at 37 °C. Cells were plated in plastic culture bottles (Costar Inc,
USA) and trypsinized every other day. Cells were seeded in the presence
of FBS, but after realizing that the serum did not change the Huh-7 cell
survival or AChE expression, the cultures were made with serum-
devoid media.2.2. Experimental design
Huh-7 and HepG2 cells were seeded at different densities (47, 105,
147, and 283 × 103 cells/cm2), and, after overnight incubation, whole
cell lysates were obtained and used forWestern blotting of AChE, cyclin
D1, p53, p21 and p27 proteins. AChE activity was measured by the
Ellman method [21]. In some experiments, the speciﬁc and reversible
AChE inhibitor 1,5-bis (4-allyldimethylammoniumphenyl) pentan-3-
one dibromide (Sigma Chem, USA) (also known as BW284C51, and re-
ferred in the present work as Bw) [22], was added to the culture media.ed at LD and HD and under serum starvation. A) Representative images and densitometry
pG2 cells. Actinwas used as loading control. Each column representsmean±SEMof three
0.001 vs LD.
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Human from normal liver, HCC and its corresponding surrounding
tissue were obtained from post mortem donors and were provided by
the Institute of Forensic Sciences (INCIFO, for its acronym in Spanish),
of the Mexico City Government, under supervision of physicians.
2.4. Western blot
Western blot was conducted as we previously reported [23]. PVDF
membranes were probed with the speciﬁc antibodies listed in the Sup-
plementary Table 1. Suitable horseradish peroxidase-conjugated anti-
bodies were used according to the primary antibodies. Blots were
revealed using Super Signal West Pico Chemiluminescent substrate
(Pierce Biotechnology, USA). Protein bands were scanned and their la-
beling intensity was quantiﬁed using a Densitometer Imaging System
(Kodak Gel Logic 1500, USA).
2.5. AChE assay
AChE activity in Huh-7 cells was measured by the Ellman method
[21]. Brieﬂy, AChE was assayed with 1 mM acetylthiocholine (Sigma
Chem, USA) and 50 μM Iso-OMPA (Sigma, Chem. USA) to inhibit
BuChE activity. Reagents and samples were added to 100 mM phos-
phate buffer, pH 8.0. The use of this buffer is advised as it keeps the
pH almost invariable along the reaction time (5–10 min). One unit
(U) of AChE activity represents the hydrolysis of 1 μmol of the substrate
per min at 37 °C.
2.6. Cell proliferation assay
The proliferation level of Huh-7 cell was examined by means of a
CCK-8 kit of Dojindo Laboratories (Kumamoto, Japan), following
manufacturer's instructions.Fig. 4. Impact of the speciﬁc AChE inhibitor Bw on the Huh-7 cell proliferation rate. A) After plat
was assayed by using CCk-8 kit at 24, 48 and 72 h. B) The content of cell cycle-related proteins
Densitometric analysis of protein content relative to actin. Each bar represents mean ± SEM of
NT or ****p ≤ 0.0001 vs NT of 72 h.2.7. Spheroid formation assay
In order to test whether AChE was capable of changing the number
or density of spheroids, 1250 Huh-7 or HepG2 cells were seeded in
each well of low adhesive 24 well plates (Costar, Inc), to which
Williams-FBS medium supplemented with 5 ng/ml epidermal growth
factor (EGF) and 5 ng/ml hepatocyte growth factor (HGF) was added.
The cultures were supplemented every 12 h with 10 μM ACh and
10 μM Bw during four days. The spheroids were counted and
photographed using an inverted microscope Carl Zeiss VERT.A1. At the
base of the culture plates were drawn quadrants in order to have an ac-
curate count.
2.8. Immunohistochemical detection of AChE
Immunohistochemical staining of AChE was performed following
routinely process as we previously reported [24], using the anti-AChE
antibody listed in Supplementary Table 1.
2.9. Protein quantiﬁcation
The protein content was determined by using the bicinchoninic acid
method (BCA, Pierce Inc.), following the manufacturer's instructions.
2.10. Statistics
The Mann Whitney test was used for assessing statistical signiﬁ-
cance of the differences in AChE activity, protein levels of cells cultured
at low or high density and proteins levels of cells cultured with the in-
hibitor of AChE. A one-way ANOVA test followed by the Bonferroni
post-test allowed us to analyze differences in the labeling intensity of
AChE bands in Western blots made with Huh-7 and HepG2 cells at dif-
ferent densities, the number of spheroids, and the changes in AChE ac-
tivity between unaffected and cancerous liver samples. A two-waying ten-thousand cells, theywere incubatedwithout andwith 10 μMBw. Cell proliferation
was evaluated byWestern blotting whole cell lysates. Representative images of the blots.
three independent experiments. Differences were considered signiﬁcant at **p≤ 0.001 vs
1384 B. Pérez-Aguilar et al. / Biochimica et Biophysica Acta 1852 (2015) 1380–1387ANOVA followed by the Bonferroni post-test was used for analyzing cell
proliferation data.
3. Results
In order to examine the possible changes in the cell morphology that
Huh-7 cells could undergo when seeded at different densities, they
were plated at 47, 105, 147, and 283 × 103 cells per cm2 as indicated
in Materials and methods. After observing that the cell morphology
was the same at any cell density (Fig. 1A–H), we tested whether the
density affected the cell viability. Although CCK-8 assays revealed that
the viability was the same regardless of the number of seeded cells
(data not shown). Western blot results indicated that the AChE protein
level had been nearly doubled (1.8-fold) at the highest cell density
(Fig. 1I–J). The lack of noticeable differences between the lower densitiesFig. 5. Impact of Bw on the formation of spheroids. 1250 Huh-7 or HepG2 cells were plated in
factor (EGF) and 5 ng/ml hepatocyte growth factor (HGF). In addition Bw(10 μM) and/or ACh (1
of at least four independent experiments in, A) Huh-7 cells; or C)HepG2 cells. Histogramswith
mean ± SEM of four independent experiments. Differences were considered signiﬁcant at *p≤prompted us to continue using plates with 47 × 103 cells/cm2, referred
from now on to as low density (LD), and with 283 × 103 cells/cm2 to as
high density (HD).
While the addition of FBS to Huh-7 cells at low density failed in
showing any noticeable change in the levels of AChE protein (Fig. 2A
and B) and activity (Fig. 2C), at high density a signiﬁcant increase in
AChE protein and a drop in AChE activity were observed, the changes
being attributed to the culture condition (HD) rather than to the addi-
tion of FBS. The opposite changes in AChE protein and activity levels ac-
cording to the selected cell density calls to caution when using cell
lineages for testing the effects of natural products, chemicals and culture
conditions on AChE expression. For assessing whether the changing
levels of AChE activity and protein according to the cell density was a
feature of Huh-7 cells or a phenomenon shared for other cell lines,
HepG2 cells were cultured as HuH-7 cells in the absence of FBS. Thelow attachment plates and were supplemented with 10% FBS, 5 ng/ml epidermal growth
0 μM)were also included. Experimentswere followed for four days. Representative images
the number of spheroids formed in B)Huh-7 cells; and D)HepG2 cells. Each bar represents
0.05 vs NT or Bw, **p ≤ 0.001 vs NT or ACh, or ****p ≤ 0.0001 vs NT or ACh.
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cells (Fig. 2D).
The reported capacity of AChE to control the cell cycle progression
[14] prompted us to explore any possible inﬂuence of AChE on the pro-
liferation of Huh-7 cells. For this, the protein levels of several cell cycle
regulators in Huh-7 cells cultured at LD and HD were assessed
(Fig. 3A). The Western blot results revealed that at HD, the content of
cyclin D1 decreased, that of p27 increased and that of p21 protein was
unchanged (Fig. 3A). Interestingly, the level of p53 was also decreased.
HepG2 cells at high density provided similar results: a signiﬁcant de-
crease in p53 alongwith a 3-fold increase in p27 (Fig. 3B). The nearly in-
variability of cyclin D1 (Fig. 3B), whose level dropped in Huh-7 cells
(Fig. 3A), and the strong decrease of cyclin A protein (Fig. 3B) in
HepG2 cells supported differences between Huh-7 and HepG2 in cell
cycle regulation. Nevertheless, themost remarkable point from the cho-
linergic point of view is the parallel changes observed in the expression
levels of AChE and cell cycle regulators, with increased levels of AChE
and p27 proteins, and decreased levels of AChE activity and cyclin D1
or cyclin A proteins, which support the idea that in cultures of Huh-7
and HepG2 cells at high density AChE contributes to cell cycle
regulation.
In our attempts to assesswhether AChE collaborated to the cell cycle
control through catalytic or noncatalytic actions the levels of AChE ac-
tivity and protein and of selected cell cycle regulators were determined
in proliferation assays made in the presence of the well-characterized
AChE inhibitor Bw [22]. The great increase in the cell number observed
when Huh-7 cells were maintained at HD for 72 h in a culture medium
containing 10 μM Bw (Fig. 4A) supported a relationship between the
drop of AChE activity (and the concurrent augment of the ACh availabil-
ity) and the increase in the cell proliferation rate. The idea of a link be-
tween the ACh availability and the level of selected cell cycle
regulators was strengthened by the observation of a statistically signif-
icant increase in the content of cyclin D1 in cells cultured at HDandwith
Bw added (Fig. 4B). Of note was the increased level of AChE and p27
proteins, but the difference with normal values was not enough as to
reach statistical signiﬁcance.
Further insight in support of the relationship of AChE and the cell
cycle progression was gained by preparing spheroids on low attach-
ment plates and testing the impact of ACh and Bw on the spheroid's
number. Contrary to the cell culture at HD, no contact inhibition takes
place in the spheroid paradigm. Despite the fact that ACh had a weak
and non-signiﬁcant effect on the spheroid formation, their number no-
tably increased in cells exposed to Bw and still more in cells cultured
with both ACh and BW added (Fig. 5A–B). The increased number ofFig. 6.AChE activity and content in samples of healthy and cancerous human liver. A) AChEwas
used. N, normal liver; ST, surrounding tumor tissue; and T, tumor tissue. Immunohistochemical
200 ×. Images are representative of at least three independent experiments. Each bar represen
****p ≤ 0.0001 vs Normal. B) Representative image of one of the liver tumors used in the studyspheroid in HepG2 cells observed in cultures containing ACh and Bw
(Fig. 5C–D) conﬁrmed the spheroid-promoting action of ACh and Bw
in cultures of hepatoma cell lines.
This increased production of spheroids allowed us to demonstrate
that there is a relationship between the loss of AChE activity (and the in-
creased availability of ACh) and the increased spheroid's number, which
might be taken like an index of tumorigenicity. This evidence alongwith
the observation of a much lower AChE activity in HCC pieces (T) than in
the surrounding tissue (ST) and normal tissue (Fig. 6A), lent strong sup-
port to the proposed anti-tumorigenic capacity of AChE owing to its
ability to decrease rapidly the level of ACh in the neighborhood of mus-
carinic and nicotinic receptors.
4. Discussion
Increased evidence suggests that AChE displays anti-tumor activi-
ty [20,25], which can arise from cancer-induced changes in the AChE ac-
tivity level, in the protein level or both. Although these changes may
arise from cancer-induced alterations in the cellular andmolecular biol-
ogy of neoplastic cells, the capacity of various cell lines, includingHuh-7
cells, to produce ACh [25] and the fact that its level was inversely corre-
lated with the AChE activity content in HCC [26] and other tumors lend
strong support to the occurrence of a causal relationship between the
drop of AChE activity and the enhanced proliferation observed in HCC
[26] and other tumors [18,27,28].
If one considers the anti-apoptosis role proposed for ACh when it
binds with mAChR and nAChR [29,30], and in the case of HCC-related
migration and invasion with androgen receptors [18], it is conceivable
that in cells whose proliferation is regulated by cholinergic activity a
persistent drop of AChE activity may inexorably lead to an enhanced di-
vision rate. This seems to be the case formetastasized lymphnode as the
result of breast cancer [31], as well as for colon cancer [32], and some
lung tumor types [33]. However, the relation of low AChE activity with
malignancy is not so obvious reminding the enhanced AChE activity ob-
served in some thymoma classes [34] and renal cell carcinoma types
[11], which in turn highlights how complex the variation of AChE ex-
pression can be in cancerous tissues.
As regards HCC malignancy, although there is evidence that AChE
works as a tumor growth suppressor in liver [18,19], the molecular
basis of this action is poorly understood especially for an enzyme
whose hepatic expression apparently changes greatly in different condi-
tions [35]. The results reported here conﬁrm the contribution of AChE to
HCC growth and support a heretofore-unreported link between the
level of AChE activity and the cyclin D1 expression level. Our dataassayed as indicated inMaterial andmethods. B) Representative image of thehuman tissue
staining of AChE in normal human liver (C) and human tumor (D). Original Magniﬁcation
ts mean ± SEM of four separate experiments. Differences were considered signiﬁcant at
.
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both AChE and the cell cycle inhibitor p27 proteins (Figs. 2 and 3),
along with a decrease in the level of cyclin D1, suggest that AChE may
directly be involved in the cell cycle control. In this regard, it has been
shown that AChE overexpression leads to decreased cell proliferation
[14,36] and anti-tumor effects [25], which opens the possibility of a di-
rect involvement of this protein in the cell cycle control.
As a model to study the effects of AChE activity changes on the cell
growth of malignant liver we used the hepatocellular carcinoma Huh-
7 cell line, whose malignant phenotype and high survival rate make
them themodel of choice for testing the beneﬁt of promising therapeu-
tic targets [37,38].Monolayer cell culture below conﬂuence is not neces-
sarily a good model to explore protein expression changes in cancer
studies owing to the fact that, contrary to cells in monolayer cultures,
cells in tumor pieces display tight cell–cell contacts, a circumstance
which probably alters the expression of many proteins. The changed
protein expression seems to be related with the increased resistance
to apoptosis- andnecrosis-inducers thatmalignant cells show. Although
themolecular basis of the protein expression changes has not been clar-
iﬁed yet, current information points to epigenetic events, particularly in
the case of HCC [19]. The longer survival displayed by a tightly-packed
mass of cellsmakes it the cell density a key factor at the time to examine
cancer-induced changes in protein expression.
Our results showing that at HD, Huh-7 and HepG2 cell cultures
displayed a higher level of AChE protein (Figs. 1J and 2A, B and D) and
a decreased level of AChE activity (Fig. 2C and D) link the drop of
AChE activity with hepatic cancer. In this regard, the opposite effects
that the high cell density have on AChE protein and activity of Huh-7
and Hep2G cells support a link between the growth of cancerous cell
lines, the increase in AChE protein and the decrease of AChE activity, a
paradox which might arise from incapacity of transformed cells to con-
vert AChE protein into catalytically competent AChE. Moreover, the
ability of AChE to bind with a range of proteins through the peripheral
anionic site (PAS), which is located near the entrance of the catalytic
gorge [39], raises the possibility that other proteins may hinder the ac-
cess of the substrate to the catalytic triad of AChE.
Whatever the case may be, the most important point is the higher
ACh level measured in HCC samples [35], which most probably arises
from a lower AChE activity, a phenomenon conﬁrmed herein (Fig. 6)
and that agreed with previous observations of Zhao's group [26]. Of
note is the fact that in cultures containing the AChE-inhibitor Bw a sig-
niﬁcant increase in the cell division rate was observed (Fig. 4), suggest-
ing that under conditions mimicking those of tumor cells, phenotype
changes lead to a drop of AChE activity, which is exacerbated when
Bw is added, and which presumably leads to cholinergic over-
activation and enhanced cell proliferation. The results of Fig. 4B showing
an association of AChE activitywith the level of cyclin D1 or cyclin A, de-
pending on the hepatoma cell line used, Huh-7 or HepG2, lend strong
support to previous data of Zhao's group. They have reported that
ERK1/2 and AKT pathways are activated in HCC lines, via ACh, so that
as long as the AChE activity increases both the activation extent of
these pathways and the level of cyclin D1 decrease [26]. Our observa-
tions showing that the drop of AChE activity is followed by an increase
of cyclin D1 or A proteins and an increase in cell proliferation as judged
by the higher number spheroids conﬁrming and extending Dr. Zhao's
results.
Thus, our proposal agrees with previous data showing that AChE
behaves as a tumor growth suppressor, which can reliably be used as
a prognostic marker for HCC, so that the lower AChE activity (and the
higher the available ACh) the higher the aggressiveness of the tumor
and enhanced risk of a poor prognosis [26]. Some reports support a
causal relationship between low AChE activity levels and enhanced
cell proliferation and tumor formation, for instance the Calaf's
group report showing that the inhibition of AChE by eserine was
capable of promoting carcinogenesis in the rat mammary gland
epithelium [40].Whenwe explored the spheroid formation inmedia containing both
ACh and Bw an increased number of spheroids was clearly observed
(Fig. 5), which lent additional support to the tumor suppressor effect
of AChE. Interestingly, the mere inhibition of AChE by Bw caused an in-
crease in both cell proliferation (Fig. 4) and the number of spheroids
(Fig. 5). Our results lend additional support to the tumor suppressor
role proposed for AChE, highlighting its importance for diminishing
the ACh level and by this means slowing the ACh mitogenic effects.
However, the possibility remains that AChEwas able to control cell pro-
liferation directly. Accumulated evidence indicates that AChE activity in
liver cancer can be considered as a reliable target for therapeutic strate-
gies due to the demonstrated capacity of AChE for slowing HCC growth.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.04.003.
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